Noercormier4179

Circuits underlying ventricular tachycardias (VTs) accompanying remote inferior myocardial infarction (IMI) are regarded to be located in the scar. Rotation around the mitral annulus (MA) had also been postulated. We tested whether entrainment mapping could confirm whether MA rotation in VTs post-IMI represented a "driving circuit."

Three patients with IMI (male, left ventricular ejection fraction range 13%-40%) with hemodynamically tolerated VT (cycle length 365-690 ms) were studied with activation and entrainment mapping of the MA.

Patients showed QRS morphologies reported for VTs following IMI LBBB (left bundle branch block) pattern and/or right bundle pattern. Entrainment revealed the entire MA perimeter constituted the circuit, that is, macroreentry (path length greater than 13 cm in one case). Alflutinib mw Areas showing prolonged fractionated electrograms (accounting for over 50% of tachycardia cycle length) demonstrated concealed entrainment indicative of slow conduction through (and not around) the scar. Concealed entrainment was observed along the MA, with similar stimulus-QRS intervals when pacing during normal sinus rhythm. Radiofrequency ablation of the inferior isthmus from scar to MA (epicardially in one case) abolished tachycardia. In follow-up, two patients had no VT recurrence and maintained NYHA Class 1 functional status during several years of follow-up. The other patient continued to deteriorate with rapidly progressive HF, had recurrent VT within 3 months, proceeding to transplant within 9 months. Our findings confirm a single-loop perimitral circuit, which is largely (if not exclusively) protected by anatomical barriers. This differs from the established "figure-of-8" VT model.

Single-loop macroreentrant mitral annular circuits may underlie some VTs following inferior wall infarcts.

Single-loop macroreentrant mitral annular circuits may underlie some VTs following inferior wall infarcts.Retraction "MicroRNA-335-5p suppresses lower extremity deep venous thrombosis by targeted inhibition of PAI-1 via the TLR4 signaling pathway," by Cui-Xia Bao, Dong-Xia Zhang, Na-Na Wang, Xiang-Kui Zhu, Qi Zhao, Xiao-Lei Sun, J Cell Biochem. 2018; 4692-4710 The above article, published online on 26 December 2017 in Wiley Online Library (https//onlinelibrary.wiley.com/doi/10.1002/jcb.26647) has been retracted by agreement between the journal's Editor in Chief, Prof. Dr. Christian Behl, and Wiley Periodicals LLC. The retraction has been agreed following an investigation based on allegations raised by a third party. A detailed investigation revealed that several image elements of the experimental data were published elsewhere in a different scientific context. Thus, the editors consider the conclusions of this article to be invalid.Retraction "High expression of TCF12 contributes to gastric cancer development via being target regulated by miR-183 and activating PI3K/AKT pathway," by Xuekui Wang, Shen Gao, Feng Xie, Wei Li, Miyang Li, Ning Yan, Tiehe Gao, and Ling Fang, J Cell Biochem. 2019; 13903-13911 The above article, published online on 15 April 2019 in Wiley Online Library (https//doi.org/10.1002/jcb.28664), has been retracted by agreement between the authors, the journal's Editor in Chief, Prof. Dr. Christian Behl, and Wiley Periodicals LLC. The retraction has been agreed after the authors asked to retract their article due to flawed data. A detailed investigation revealed multiple inappropriate modifications especially in the backgrounds of blots. Since original data could not be provided, the overall validity of the results could not be confirmed. The authors were not available for a final confirmation of the retraction.Retraction "MicroRNA-539 promotes osteoblast proliferation and differentiation and osteoclast apoptosis through the AXNA-dependent Wnt signaling pathway in osteoporotic rats," by Xiong-Bai Zhu, Wen-Jun Lin, Chen Lv, Lu Wang, Zheng-Xiang Huang, Sheng-Wu Yang, Xin Chen, J Cell Biochem. 2018; 8346-8358 The above article, published online on 12 June 2018 in Wiley Online Library (https//onlinelibrary.wiley.com/doi/10.1002/jcb.26910) has been retracted by agreement between the journal's Editor in Chief, Prof. Dr. Christian Behl, and Wiley Periodicals LLC. The retraction has been agreed following an investigation based on allegations raised by a third party. A detailed investigation revealed that several image elements of the experimental data were published elsewhere in a different scientific context. Thus, the editors consider the conclusions of this article to be invalid.Despite decades of research since its first description, subtalar joint instability remains a diagnostic enigma within the concept of hindfoot instability. This could be attributed to current imaging techniques, which are impeded by two-dimensional measurements. Therefore, we used weightbearing computed tomography imaging to quantify three-dimensional displacement associated with subtalar joint instability. Three-dimensional models were generated in seven paired cadaver specimens to compute talocalcaneal displacement after different patterns of axial load (85 kg) combined with torque in internal and external rotation (10 Nm). Sequential imaging was repeated in the subtalar joint containing intact ligaments to determine reference displacement. Afterward, the interosseus talocalcaneal ligament (ITCL) or calcaneofibular ligament (CFL) was sectioned, then the ITCL with CFL and after the ITCL, CFL with the deltoid ligament (DL). The highest translation could be detected in the dorsal direction and the highest rotation occurred in the internal direction when external torque was applied to the foot without load. These displacements differed significantly from the condition containing intact ligaments, with a mean difference of 1.6 mm (95% CI, 1.3 to 1.9) for dorsal translation and a mean of 12.4° (95% CI, 10.1 to 14.8) for internal rotation. Clinical relevance Our study provides a novel and noninvasive analysis to quantify subtalar joint instability based on three-dimensional WBCT imaging. This approach overcomes former studies using trans-osseous fixation to determine three-dimensional subtalar joint displacement and implements an imaging device and software modalities that are readily available. Based on our findings, we recommend applying torque in external rotation to the foot to optimize the detection of subtalar joint instability.The mechanical advantage of the knee extensor mechanism depends heavily on the patellar tendon moment arm (PTMA). Understanding which factors contribute to its variation may help improve functional outcomes following arthroplasty. This study optimized PTMA measurement, allowing us to quantify the contribution of different variables. The PTMA was calculated about the instantaneous helical axis of tibiofemoral rotation from optical tracked kinematics. A fabricated knee model facilitated calculation optimization, comparing four data smoothing techniques (raw, Butterworth filtering, generalized cross-validated cubic spline-interpolation and combined filtering/interpolation). The PTMA was then measured for 24 fresh-frozen cadaveric knees, under physiologically based loading and extension rates. Combined filtering/interpolation enabled sub-mm PTMA calculation accuracy throughout the range of motion (root-mean-squared error 0.2 mm, max error 0.4 mm), whereas large errors were measured for raw, filtered-only and interpolated-only techniques at terminal flexion/extension. Before scaling, the mean PTMA was 46 mm; PTMA magnitude was consistently larger in males (mean differences 5 to 10 mm, p  less then  .05) and was strongly related to knee size larger knees have a larger PTMA. However, while scaling eliminated sex differences in PTMA magnitude, the peak PTMA occurred closer to terminal extension in females (female 15°, male 29°, p = .01). Knee size accounted for two-thirds of the variation in PTMA magnitude, but not the flexion angle where peak PTMA occurred. This substantial variation in angle of peak PTMA has implications for the design of musculoskeletal models and morphotype-specific arthroplasty. The developed calculation framework is applicable both in vivo and vitro for accurate PTMA measurement.Retraction "Effects of microRNA-24 targeting C-myc on apoptosis, proliferation, and cytokine expressions in chondrocytes of rats with osteoarthritis via MAPK signaling pathway," by Yuan-Hao Wu, Wei Liu, Lei Zhang, Xiao-Ya Liu, Yi Wang, Bin Xue, Bin Liu, Ran Duan, Bo Zhang, Yang Ji, J Cell Biochem. 2018; 7944-7958 The above article, published online on 16 November 2017 in Wiley Online Library (https//onlinelibrary.wiley.com/doi/10.1002/jcb.26514) has been retracted by agreement between the the journal's Editor in Chief, Prof. Dr. Christian Behl, and Wiley Periodicals LLC. The retraction has been agreed following an investigation based on allegations raised by a third party. A detailed investigation revealed that several image elements of the experimental data were published elsewhere in a different scientific context. Thus, the editors consider the conclusions of this article to be invalid.

Solriamfetol is approved (US and EU) for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea.

Evaluate solriamfetol safety/efficacy for EDS in Parkinson's disease (PD).

Phase 2, double-blind, 4-week, crossover trial adults with PD and EDS were randomized to sequence A (placebo, solriamfetol 75, 150, 300 mg/d), B (solriamfetol 75, 150, 300 mg/d, placebo), or C (placebo). Outcomes (safety/tolerability [primary]; Epworth Sleepiness Scale [ESS]; Maintenance of Wakefulness Test [MWT]) were assessed weekly. P values are nominal.

Common adverse events (n=66) nausea (10.7%), dizziness (7.1%), dry mouth (7.1%), headache (7.1%), anxiety (5.4%), constipation (5.4%), dyspepsia (5.4%). ESS decreased both placebo (-4.78) and solriamfetol (-4.82 to -5.72; P >0.05). MWT improved dose-dependently with solriamfetol, increasing by 5.05 minutes with 300 mg relative to placebo (P =0.0098).

Safety/tolerability was consistent with solriamfetol's known profile. There were no significant improvements on ESS; MWT results suggest possible benefit with solriamfetol in PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Safety/tolerability was consistent with solriamfetol's known profile. There were no significant improvements on ESS; MWT results suggest possible benefit with solriamfetol in PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.This study evaluated the accuracy of synthetic computed tomography (sCT), as compared to CT, for the 3D assessment of the hip morphology. Thirty male patients with asymptomatic hips, referred for magnetic resonance (MR) imaging and CT, were included in this retrospective study. sCT images were generated from three-dimensional radiofrequency-spoiled T1-weighted multi-echo gradient-echo MR images using a commercially available deep learning-enabled software and were compared with CT images through mean error and surface distance computation and by means of eight clinical morphometric parameters relevant for hip care. Parameters included center-edge angle (CEA), sharp angle, acetabular index, extrusion index, femoral head center-to-midline distance, acetabular version (AV), and anterior and posterior acetabular sector angles. They were measured by two senior orthopedic surgeons and a radiologist in-training on CT and sCT images. The reliability and agreement of CT- and sCT-based measurements were assessed using intraclass correlation coefficients (ICCs) for absolute agreement, Bland-Altman plots, and two one-sided tests for equivalence.